… (αManII) overexpression was found to bring about the highest level of bisecting and afucosylated
glycans on IgG antibodies, and has been translated into the commercialized anti-CD20 …

… -fucosylated version of this chimeric antibody showed enhanced CDC and ADCC comparable
to non-fucosylated … , where an anti-CD20 113F antibody construct showed greater B cell …

… for manufacturing afucosylated therapeutic antibodies whose … Yet, in a “less-is-more”
fashion, human IgG1 lacking core … for the development of innovative anti-cancer drugs. Table 1 …

… Despite these caveats, it is worth noting that afucosylated or low fucose anti-cancer mAbs
have … mAbs (124), as well as the development of new afucosylated therapeutic antibodies in a …

… used for cancer therapy, evaluated as the serum concentration of antidrug antibodies, is …
A reduced percentage of fucosylated oligosaccharides in the Fc of IgG1 enhances ADCC, …

… afucosylated mAbs did not change their ADCC activity 138 . These results indicated the
importance of afucosylation … achieved with mAb-based anti-cancer therapies in the last ten years …

… 4.1.2), the highly fucosylated glycoprofile of CHO cell produced antibodies has led to … to
produce afucosylated mAbs to treat cancer via ADCC. By contrast, anti-cancer IgG antibodies …

… The most relevant modification is afucosylation of N297 glycan which significantly
increased the … Two afucosylated mAbs already received marketing approval (mogamulizumab19, …

… enhanced ADCC of afucosylated antibodies. Engineered afucosylated IgG1 antibodies bind
with … after, such as anti-cancer and anti-bacterial drug discovery. Considering the scientific, …

… the antibody’s anti-cancer efficacy. MUC1 is an interesting target for antibody-based anti-cancer
therapy, as it … , the latter two antibodies have not been directly compared to fucosylated …